The Federal Trade Commission (FTC) has announced a November 8 workshop that will focus on competition issues related to prescription drug marketing.
The Federal Trade Commission (FTC) has announced a November 8 workshop that will focus on competition issues related to prescription drug marketing.
The workshop, titled Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics, will feature keynotes by acting FTC Chairperson Maureen K. Ohlhausen and FDA Commissioner Scott Gottlieb, MD.
The workshop will address issues related to both the Hatch-Waxman Act (which provides a framework for generic entry into the small-molecule drug market) and the Biologics Price Competition and Innovation Act (which provides a pathway for biosimilar product entry). The first session of the workshop will focus on generic drug markets and factors that could preclude entry of generic competitors after an innovator product’s patents have expired, and will include discussion of non-price factors that can impact market entry. The second session will evaluate the role of intermediaries including pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs) in drug prices for consumers.
“Competition is key to containing prescription drug costs. During the last decade, generic drugs have saved Americans more than $1.67 trillion,” said Ohlhausen. “In light of concerns about rising drug prices, it's critical [that] we identify barriers that may prevent drugs from entering the market, even after applicable patent protections have expired.”
In announcing his participation in the panel on Twitter, Gottlieb said that he looked forward to working together with the commission:
In a statement, Gottlieb elaborated further, saying that he welcomed the opportunity to take part in the FTC’s workshop as a way to help identify obstacles to competition, and that “I am committed to doing all we can under the FDA’s authority to help reduce the burden on consumers, so that no patient is ever priced out of access to a medicine they need to cure a disease or maintain their health.”
Such cooperation between the FDA and FTC is a welcome development for those hoping for greater regulatory attention paid to prescription drug pricing. Elizabeth Jex, JD, attorney advisor for the FTC’s office of policy planning said at September’s Association for Accessible Medicines Biosimilars Council Conference 2017 meeting in Washington, DC, that “There’s been an uptick of coordination” between the agencies under current leadership, and that the FTC might be close to disclosing more information about collaborative efforts.
Jex said that “The commission and I share concerns about anticompetitive conduct” with respect to prescription drug competition for biosimilars and biologics. Speaking for herself, Jex expressed concern that reimbursement systems, including rebate arrangements, are “chilling price competition” for such therapies.
The workshop will be held at the FTC’s Constitution Center Auditorium in Washington, DC, and is both free and open to the public.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.